Abstract
The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) (Aug. 24 issue of NEJM) was a global trial that assessed pitavastatin calcium as compared with placebo to prevent major adverse cardiovascular events (MACE) among participants with HIV who were at low-to-moderate predicted cardiovascular risk. This report updates the published analysis with final data regarding efficacy and safety outcomes, including all participant follow-up.